drug

Physical and neuro-cognitive evaluations

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
BEHAVIORAL
Pre-approval / investigational in the US
Developed by The Methodist Hospital Research Institute
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
BEHAVIORAL

Indications

Trials

1
Ocrelizumab for Psychosis by Autoimmunity
NCT03971487Phase 1, Phase 2Recruiting

KOLs & investigators

1
Joseph C Masdeu, MD, PhD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
The Methodist Hospital Research Institute
company
trial
Ocrelizumab for Psychosis by Autoimmunity
PHASE1, PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizo-Affective Type of Psychosis
indication
KOL
Joseph C Masdeu, MD, PhD
KOL score —
person